Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?
Clinical and Experimental Immunology · 20.06.2024 · 217 (1) · 15-30
DOI: 10.1093/cei/uxae031 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 20.04.2024. Verfasst von Kavina Shah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Rheumatology, UCLH, London,UK. Hauptthemen laut MEDLINE: Autoimmune Diseases, B-Lymphocytes, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Research UK, Medical Research Council.
Abstract (Originalsprache)
B and T cells collaborate to drive autoimmune disease (AID). Historically, B- and T-cell (B–T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B-cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and organ transplantation benefit from targeted BCD with anti-CD20 monoclonal antibodies such as rituximab, ocrelizumab, or ofatumumab. Refractory AID is a significant problem for patients with incomplete BCD with a greater frequency of IgD−CD27+ switched memory B cells, CD19+CD20− B cells, and plasma cells that are not directly targeted by anti-CD20 antibodies, whereas most lymphoid tissue plasma cells express CD19. Furthermore, B–T-cell collaboration is predominant in lymphoid tissues and at sites of inflammation such as the joint and kidney, where BCD may be inefficient, due to limited access to key effector cells. In the treatment of cancer, chimeric antigen receptor (CAR) T-cell therapy and T-cell engagers (TCE) that recruit T cells to induce B-cell cytotoxicity have delivered promising results for anti-CD19 CAR T-cell therapies, the CD19 TCE blinatumomab and CD20 TCE such as mosunetuzumab, glofitamab, or epcoritamab. Limited evidence suggests that anti-CD19 CAR T-cell therapy may be effective in managing refractory AID whereas we await evaluation of TCE for use in non-oncological indications. Therefore, here, we discuss the potential mechanistic advantages of novel therapies that rely on T cells as effector cells to disrupt B–T-cell collaboration toward overcoming rituximab-resistant AID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Rheumatology, UCLH, London,UK.
- Department of Rheumatology, University College London Hospital, London, UK.
- University of Southampton Faculty of Medicine, Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, Southampton, UK.
- Roche Innovation Center Basel, Early Development Immunology, Infectious Diseases & Ophthalmology, Basel, Switzerland.
- Roche Innovation Center Basel, Roche Pharma Research and Early Development, Schlieren, Switzerland.
- Roche Innovation Center Zurich, Cancer Immunotherapy Discovery, Oncology Discovery & Translational Area, Schlieren, Switzerland.
ORCID-Profile: Venkat Reddy
Förderung
- Cancer Research UK
- Medical Research Council
Zitieren
APA
Shah, K., Leandro, M., Cragg, M., Kollert, F., Schuler, F., Klein, C., & Reddy, V. (2024). Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?. Clinical and Experimental Immunology, 217(1), 15-30. https://doi.org/10.1093/cei/uxae031
Vancouver
Shah K, Leandro M, Cragg M, Kollert F, Schuler F, Klein C, et al. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?. Clinical and Experimental Immunology. 2024;217(1):15-30. doi:10.1093/cei/uxae031
BibTeX
@article{Shah2024,
author = {Shah, Kavina and Leandro, Maria and Cragg, Mark and Kollert, Florian and Schuler, Franz and Klein, Christian and Reddy, Venkat},
title = {Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?},
journal = {Clinical and Experimental Immunology},
year = {2024},
volume = {217},
number = {1},
pages = {15--30},
doi = {10.1093/cei/uxae031}
}
EUVIMED